Specific oxidative stress profile associated with partial striatal dopaminergic depletion by 6-hydroxydopamine as assessed by a novel multifunctional marker molecule

References

• Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 2003;991:120–131.
   PubMed Web of Science ®Google Scholar
• Schapira AH. Mitochondrial dysfunction in neurodegenerative disorders. Biochim Biophys Acta 1998;1366:225–233.
   PubMed Web of Science ®Google Scholar
• Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990;40(suppl):32–37;discussion 37–39.
   PubMedGoogle Scholar
• Dexter DT, Sian J, Jenner P, Marsden CD. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol 1993;60:273–281.
   PubMedGoogle Scholar
• Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann NY Acad Sci 2004; 1012:306–325.
   PubMed Web of Science ®Google Scholar
• Mayo JC, Sainz RM, Tan DX, Antolin I, Rodriguez C, Reiter RJ. Melatonin and Parkinson's disease. Endocrine 2005;27:169–178.
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts. Arch Biochem Biophys 1986;246:501–514.
   PubMed Web of Science ®Google Scholar
• Khatib S, Musa R, Vaya J. An exogenous marker: a novel approach for the characterization of oxidative stress. Bioorg Med Chem 2007;15:3661–3666.
   PubMed Web of Science ®Google Scholar
• Szuchman A, Aviram M, Musa R, Khatib S, Vaya J. Characterization of oxidative stress in blood from diabetic vs. hypercholesterolaemic patients, using a novel synthesized marker. Biomarkers 2008;13:119–131.
   PubMed Web of Science ®Google Scholar
• Szuchman A, Aviram M, Soliman K, Tamir S, Vaya J. Exogenous N-linoleoyl tyrosine marker as a tool for the characterization of cellular oxidative stress in macrophages. Free Radic Res 2006;40:41–52.
   PubMed Web of Science ®Google Scholar
• Szuchman A, Aviram M, Tamir S, Vaya J. Cholesterol, linoleic acid or/and tyrosine yield different spectra of products when oxidized alone or in a mixture: studies in various oxidative systems. Free Radic Res 2003;37:1277–1288.
   PubMed Web of Science ®Google Scholar
• Vaya J, Schipper HM. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 2007;102:1727–1737.
   PubMed Web of Science ®Google Scholar
• Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004;46:54–63.
   Web of Science ®Google Scholar
• Paxinos G, Watson C. The rat brain in stereotaxic coordinates. 4th. San Diego: Academic Press; 1998.
   Google Scholar
• Hammermeister DE, Serrano J, Schmieder P, Kuehl DW. Characterization of dansylated glutathione, glutathione disulfide, cysteine and cystine by narrow bore liquid chromatography/electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 2000;14:503–508.
   PubMedGoogle Scholar
• Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, Milo S. Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins. Free Radic Res 2001;34:485–497.
   PubMed Web of Science ®Google Scholar
• Addis PB, Emanuel HA, Bergmann SD, Zavoral JH. Capillary GC quantification of cholesterol oxidation products in plasma lipoproteins of fasted humans. Free Radic Biol Med 1989; 7:179–182.
   PubMed Web of Science ®Google Scholar
• Tavori H, Aviram M, Khatib S, Musa R, Nitecki S, Hoffman A, Vaya J. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic Biol Med 2009;46:607–615.
   PubMed Web of Science ®Google Scholar
• Sayre LM, Perry G, Smith MA. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008;21:172–188.
   PubMed Web of Science ®Google Scholar
• Yasuhara T, Hara K, Sethi KD, Morgan JC, Borlongan CV. Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats. Brain Res 2007;1133:49–52.
   PubMed Web of Science ®Google Scholar
• Sanchez-Iglesias S, Rey P, Mendez-Alvarez E, Labandeira-Garcia JL, Soto-Otero R. Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem Res 2007; 32:99–105.
   PubMed Web of Science ®Google Scholar
• Smith MP, Cass WA. Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson's disease. Neuroscience 2007;144:1057–1066.
   PubMed Web of Science ®Google Scholar
• Garcia JC, Remires D, Leiva A, Gonzalez R. Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease. J Mol Neurosci 2000;14:147–153.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ogawa N, Asanuma M. Molecular basis of 6-hydroxydopamine-induced caspase activations due to increases in oxidative stress in the mouse striatum. Neurosci Lett 2006;410:85–89.
   PubMed Web of Science ®Google Scholar
• Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305–310.
   PubMed Web of Science ®Google Scholar
• Stricker EM, Zigmond M. Recovery of function after damage to central catecholamine-containing neurons: a neurochemical model for the lateral hypothalamic syndromeSprague J, Epstein A. Progress in psychobiology and physiological psychology. New York: Academic Press; 1976. 121–187.
   Google Scholar
• Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology 2009;72 (7 Suppl):S32–S38.
   PubMedGoogle Scholar
• Zigmond MJ, Abercrombie ED, Stricker EM. Partial damage to nigrostriatal bundle: compensatory changes and the action of L-dopa. J Neural Transm Suppl 1990;29:217–232.
   PubMedGoogle Scholar
• Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984;41:856–861.
   PubMedGoogle Scholar
• Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003;26:215–221.
   PubMed Web of Science ®Google Scholar
• Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in parkinson's disease. Exp Neurol 2001;169:163–181.
   PubMed Web of Science ®Google Scholar
• Garris PA, Walker QD, Wightman RM. Dopamine release and uptake rates both decrease in the partially denervated striatum in proportion to the loss of dopamine terminals. Brain Res 1997;753:225–234.
   PubMed Web of Science ®Google Scholar
• Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003;5:165–176.
   PubMed Web of Science ®Google Scholar
• Wan FJ, Tung CS, Shiah IS, Lin HC. Effects of alpha-phenyl-N-tert-butyl nitrone and N-acetylcysteine on hydroxyl radical formation and dopamine depletion in the rat striatum produced by d-amphetamine. Eur Neuropsychopharmacol 2006;16:147–153.
   PubMed Web of Science ®Google Scholar
• Kostrzewa RM, Kostrzewa JP, Brus R. Dopaminergic denervation enhances susceptibility to hydroxyl radicals in rat neostriatum. Amino Acids 2000;19:183–199.
   PubMed Web of Science ®Google Scholar
• Nowak P, Szczerbak G, Biedka I, Drosik M, Kostrzewa RM, Brus R. Effect of ketanserin and amphetamine on nigrostriatal neurotransmission and reactive oxygen species in Parkinsonian rats. In vivo microdialysis study. J Physiol Pharmacol 2006;57:583–597.
   PubMed Web of Science ®Google Scholar
• DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007;64:20–24.
   PubMedGoogle Scholar